AU638728B2 - Anthelmintic non-living vaccine - Google Patents
Anthelmintic non-living vaccineInfo
- Publication number
- AU638728B2 AU638728B2 AU59614/90A AU5961490A AU638728B2 AU 638728 B2 AU638728 B2 AU 638728B2 AU 59614/90 A AU59614/90 A AU 59614/90A AU 5961490 A AU5961490 A AU 5961490A AU 638728 B2 AU638728 B2 AU 638728B2
- Authority
- AU
- Australia
- Prior art keywords
- vaccine
- antigen
- sheep
- ostertagia circumcincta
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960005486 vaccine Drugs 0.000 title claims description 36
- 230000000507 anthelmentic effect Effects 0.000 title description 6
- 239000000427 antigen Substances 0.000 claims description 69
- 102000036639 antigens Human genes 0.000 claims description 69
- 108091007433 antigens Proteins 0.000 claims description 69
- 241000191771 Teladorsagia circumcincta Species 0.000 claims description 51
- 241001465754 Metazoa Species 0.000 claims description 27
- 241000244206 Nematoda Species 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 19
- 244000045947 parasite Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 229920004890 Triton X-100 Polymers 0.000 claims description 14
- 239000013504 Triton X-100 Substances 0.000 claims description 14
- 239000003599 detergent Substances 0.000 claims description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 13
- 241000243974 Haemonchus contortus Species 0.000 claims description 10
- 230000001524 infective effect Effects 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 241000243796 Trichostrongylus colubriformis Species 0.000 claims description 7
- 230000002496 gastric effect Effects 0.000 claims description 6
- 230000002503 metabolic effect Effects 0.000 claims description 6
- 230000003248 secreting effect Effects 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 230000000392 somatic effect Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 241001494479 Pecora Species 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 239000000499 gel Substances 0.000 description 23
- 238000003119 immunoblot Methods 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 235000013601 eggs Nutrition 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 238000002649 immunization Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000283903 Ovis aries Species 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000004929 secretory organelle Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 238000011887 Necropsy Methods 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001707 blastogenic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000001418 larval effect Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 208000030852 Parasitic disease Diseases 0.000 description 4
- 241000282849 Ruminantia Species 0.000 description 4
- -1 alkyl phenol Chemical compound 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 230000003071 parasitic effect Effects 0.000 description 4
- 238000007790 scraping Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000244030 Toxocara canis Species 0.000 description 3
- 210000003165 abomasum Anatomy 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000011536 extraction buffer Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- 241000244203 Caenorhabditis elegans Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 241000243777 Trichinella spiralis Species 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036281 parasite infection Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 235000020030 perry Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CTRXDTYTAAKVSM-UHFFFAOYSA-N 3-{[ethyl({4-[(4-{ethyl[(3-sulfophenyl)methyl]amino}phenyl)(2-sulfophenyl)methylidene]cyclohexa-2,5-dien-1-ylidene})azaniumyl]methyl}benzene-1-sulfonate Chemical compound C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S(O)(=O)=O)C=CC=1N(CC)CC1=CC=CC(S(O)(=O)=O)=C1 CTRXDTYTAAKVSM-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000243976 Haemonchus Species 0.000 description 1
- 108010034145 Helminth Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000000291 Nematode infections Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001523956 Parengyodontium album Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241001126266 Strongyloidea Species 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 241000243774 Trichinella Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- FVDYHOGCIRNKAY-UHFFFAOYSA-N benzyl thiohypofluorite Chemical compound FSCC1=CC=CC=C1 FVDYHOGCIRNKAY-UHFFFAOYSA-N 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 229940105402 brillant blue Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000002061 histotrophic effect Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003108 parasitologic effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 229940096911 trichinella spiralis Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ANTHELM1NTIC NON-LIVING VACCINE
FIELD OF THE INVENTION
This invention relates to vaccines and in particular to anthelmintic veterinary non-living vaccines. The invention also relates to methods of treating animals.
BACKGROUND OF THE INVENTION
Gastrointestinal roundworms (nematodes) are parasites which are found in farm animals and in man, and are the cause of a variety of diseases. Infestation with gastrointestinal roundworms and in particular Ostertagia circumcincta is a major cause of parasitic disease and production losses in the sheep industry, especially in the winter rainfall areas of Australia and other similar climatic areas around the world. Chemical drenches have been extensively used to control this gastrointestinal roundworm parasite since the 1960s with the consequence that drench-resistant parasites are now wide spread and threatening the viability of this industry. The development of an effective anthelmintic vaccine is regarded as one of very few alternative options to save the industry.
Previous workers have developed anthelmintic vaccines which have proven unsatisfactory in practise. One such vaccine is described in a United States Patent No. 3,395,218 (Silverman), granted July 30, 1968. This patent describes the preparation of a non-living vaccine produced by in vitro incubation of third-stage infective nematode larvae into histotrophic stages in an aqueous medium, and then removing the larvae and lyophilising the used aqueous medium. Similarly, a UK Patent Specification 1580539 granted 22 June
1977 describes the preparation of metabolic antigens excreted/secreted by either infective Trichinella spiralis or Haemonchus contortus larvae cultured in a synthetic medium. These antigens are claimed to be useful as an oral vaccine against T. spiralis and other helminth parasites of mammals.
SUBSTITUTE SHEET
PCT Application (No PCT/AU85/00282, International Publication No. WO86/02839) by Biotechnology Australia Pty Ltd describes a vaccine comprising a suspension, homogenate or extract of a nematode species which is non-parasitic to mammals or birds. This preparation is claimed to be useful for vaccination against nematode species which are parasitic to mammals and birds.
It is now well known that such preparations contain a great number of different substances, and are therefore antigenetically complex (Anders, Howard & Mitchell, 1982). Only a very small minority of the many antigens present in this prior art preparation may be capable of promoting host-protective immune responses, while the majority generally induce inconsequential or pro-parasitic immune responses which may enhance the worm's ability to survive and/or mediate and produce the pathological lesions responsible for disease. Therefore, a vaccine prepared from such a mixture may not even protect the host from a subsequent challenge infection, let alone be an efficacious vaccine.
In the last few years, considerable efforts have been made towards the identification of individual proteins or groups of proteins which are identical in certain physio-chemical characteristics present in roundworm parasites and which may induce responses in the host animal to protect it from re-infection. A sodium-deoxycholate soluble 41 kilodaiton tropomyosin - like molecule extracted from third stage Trichostronαylus colubriformis larvae was shown to induce 43-51% protection in guinea pigs following immunisation (O'Donnell, Dineen, Wagland, Letho, Werkmeister and Ward 1989). In international patent application .
WO 89/00163 filed in respect of this molecule, a claim was made that sheep and other mammals can also be protected against parasitic nematode infections when they were immunised with this 41 kilodaiton molecule. In a recent report, a 94 kilodaiton excretory- secretory product of exsheathed third stage T. colubriformis larvae was claimed to induce a mean level of protection of 46% in guinea pigs (O'Donnell, Dineen, Wagland, Letho,
Dopheide, Grant and Ward 1989). However, the ability of this latter molecule to protect sheep and other animals is not known.
PCT Application No. WO 88/00835 (Munn, E.A.) describes a protein doublet (H110D) isolated from the plasma membrane of the intestinal microvilli of Haemonchus contottus. H110D has a molecular weight of about 110 kilodaltons, and this material is claimed to protect lambs against haemonchosis when animals are injected with either components of H110D or the whole protein doublet H100D.
SUBSTITUTE SHEET
However in all of these reports, the protection observed with each preparation is marginal. In all cases, the molecule is identified initially as being the most prominent protein component when the crude parasite preparation is analysed. It is obvious that there are other parasite components, including those which are not among the major components of any parasite preparation, that also play a significant role in conferring the near absolute protection one generally observes in the natural host-parasite relationship where immunological resistance is induced by a normal infection. In this latter situation the host can be exposed to a series of parasite proteins and therefore respond accordingly as the parasite grows and develops.
There is therefore a need to identify parasite antigens which are differentially recognised by the immunological mechanism of resistant animals compared with susceptible animals. These antigens are the protective antigens and should form the basis of any vaccines against nematode parasite infections in sheep, cattle and other domesticated animals.
Accordingly, it is an object of the present invention to provide an effective anthelmintic vaccine.
SUMMARY OF THE INVENTION
This invention provides in one form a non-living anthelmintic vaccine comprising an immunologically effective amount of a proteinaceous antigen of molecular weight about 31 kilodaiton as determined by SDS-PAGE extracted from species of gastrointestinal nematode parasites belonging to the phylum Nemathelminthes, class Nematoda, order Strongyloidea, together with a veterinary diluent or carrier therefore.
Preferably the species is selected from the group comprising Ostertagia circumcincta. Haemonchus contortus. and Trichostronαylus colubriformis.
More preferably the species is Ostertagia circumcincta
More preferably the species is Ostertagia circumcincta at the third larval stage.
Preferably the antigen is an excretory, secretory or metabolic product of Ostertagia circumcincta.
More preferably the antigen is an intracellular, somatic and membraneous extract of Ostertagia circumcincta.
In a preferred embodiment the antigen is an alkyl phenol ethoxylate extract, especially iso-
SUBSTSTUTE SHEET
octylphenol ethoxylate.
More preferably the antigen includes 5-15% sugar content as measured by phenol/sulphuric acid assays for hexose sugars.
More preferably the sugar content is composed of inositol, mannose, galactose and hexosamine as measured by GC-mass spectrophotometry.
Preferably the vaccine further comprises adjuvants, especially saponin.
In an alternative form the invention provides a method of treating ruminants against the occurrence of nematode parasites by administering an effective dose of the vaccine as described above, thereby eliciting an immune response.
Preferably the ruminants are sheep. Whilst the vaccine of this invention has most economic value with ruminants it is useful for other mammals as well.
Preferably the method comprises administering a low dose of said vaccine.
Preferably the dose level is less than 400^g of the said antigen or its individual components thereof.
The molecular weight of the proteinaceous antigen which may consist of a number of different molecules according to the invention is approximately 31 kilodaiton. The preferred method of measuring molecular weight is that of Laemmli (1970) which uses polyacryiamide gel mixed with 10% sodium dodecyl sulphate (SDS). This technique has been found- to provide consistent results ± 1000 daltons but it should be realised that the molecular weights may vary by two or more thousand daltons. In gel fractionation studies there is evidence that the proteinaceous antigen may be a protein doublet. The term proteinaceous antigen is used in a broad sense and the term includes glycoprotein as a component of the gel fraction.
It is believed that the proteinaceous antigen of the present invention comprises a mixture of proteins of similar molecular weight of about 31 kilodaiton. These proteins may be fractionated by two dimensional SDS-poiyacrylimide gel electrophoresis into at least 10 components with different apparent pi values.
The vaccines according to the present invention may be administered parentally or orally.
Preferably the vaccine further comprises molecules derived from the group comprising Ostertagia circumcincta. Haemonchus contortus. Trichostronoylus colubriformis and other
SUBSTITUTE SHEET I
nematode species. It is likely that other molecules, unrelated to the said proteinaceous antigen may also induce a protective immune response in ruminants and that a cocktail vaccine comprising these other molecules together with the proteinaceous antigen or Its components may also be an effective vaccine.
The invention will be further described by reference to a preferred EΞxample.
BRIEF DESCRIPTION OF THE DRAWINGS
The accompanying drawings are reproductions of SDS-PAGE and immunoblot profiles (Figures 1-5 and 8), photomicrographs of immuno-stained worm sections (Figures 6 and 7), Elisa antibody responses of sheep (Figure 9), and comparison of faecal egg outputs between immunised and control sheep (Figure 10).
FIGURE 1 illustrates protein and antigen profiles of third stage infective larvae and adult Ostertagia circumcincta Triton X-100 sonicates. Protein profiles (lanes A & C) are revealed by staining with Coomassie Brillant Blue after SDS-PAGE separation. Antigen profiles (lanes B & D) are revealed using pooled sera from Ostertagia circumcincta infected sheep with the immunoblot technique (see Materials and Methods section). Numbers on the left margin are molecular weight standards expressed in thousands.
FIGURE 2 illustrates the immunoblot identification of antigens in Triton X-100 sonicates from third stage (lanes B, D & F) and adult (lanes A, C & E) Ostertagia circumcincta using sera from experimentally infected resistant sheep (lanes A & B), infected susceptible sheep (lanes C & D), and uninfected worm-free sheep (lanes E & F). Note the strongly stained 31 kDa molecule (arrow) from third stage larval extract revealed by sera from resistant sheep. Numbers on left margin are molecular weight standards expressed in thousands.
FIGURE 3 illustrates the profiles of the 31 kilodaiton (kDa) proteinaceous antigen (OC31) of third stage Ostertagia circumcincta larvae on a 10% (lane A) and a 15% (lane B) SDS- PAGE gel after staining with coomassie brillant blue. Note the doublet appearance of this protein after separation on a 15% gel. The protein doublet consists of two very closely associated antigenic bands as revealed by immunoblotting using monospecific OC31 rabbit antiserum (lane C). Molecular standards are indicated (kDa).
SUBSTITUTE SHEET
FIGURE 4 illustrates the appearance of antibodies to the 31 kDa proteinaceous antigen (OC31) in resistant sheep following experimental infection as detected by the immunoblot technique.
FIGURE 5 illustrates the effects of Proteinase K or Periodate oxidation treatments on the antigenicity of OC31 molecule in Triton X-100 extracts of third stage O. circumcincta larvae as detected by the immunoblot technique. The left lane of each treatment is the extract without the respective treatment
FIGURE 6 illustrates the localisation of proteinaceous antigen OC31 using indirect fluorescent antibody staining technique. Transverse sections of third-stage larvae of Ostertagia circumcincta were reacted with monospecific rabbit antiserum against OC31, washed to rid excess antibodies, and the reaction was then detected with a flouresein conjugated anti-rabbit immunoglobulin antiserum. The image was obtained using a laser scanning microscope with confocal imaging system. Note interal location of fluorescence. Scale bar is 3/ιm.
FIGURE 7 illustrates the localisation of proteinaceous antigen OC31 using immunoelectron micrography:
a. Transverse section of third-stage Ostertagia circumcincta taken from the anterior pharyngeal region reacted with OC31 monospecific rabbit antisera and protein A-gold labelled conjugate. Note triradiate lumen of the oesophagus and darkly stained secretory organelles. Scale bar is 3/ m.
b. Higher magnification of one of the darkly stained secretory organelles (arrow). Scale bar is 0.3μm.
FIGURE 8 illustrates an autoradiograph of an immunoblot, probed with resistant sheep serum and developed using protein G 125l (Amersham), showing the predominant 31 kDa molecule OC31 (arrow) of third stage Ostertagia circumcincta (lane A) present in Triton X-
100 extracts of third stage larvae of TrichostrongyJus colubriformis (lane B) and Haemonchus contortus (lane C), but not present in second stage larvae of Toxocara canis (lane D).
FIGURE 9 illustrates the ELISA antibody responses between immunised and control sheep.
FIGURE 10 illustrates the faecal nematode egg outputs between immunised and control sheep.
SUBSTITUTE SK EET
MATERIALS AND METHODS
a. Parasite Materials
The Ostertagia circumcincta strain used in this study has been maintained at the Regional Veterinary Laboratory, Hamilton since 1984. It originated from a naturally infected sheep reared in Western Victoria. Approximately 500 live male and female adult Ostertagia circumcincta were recovered from this sheep at necropsy and surgically transplanted into the abomasum of a worm-free sheep. The parasite life cycle was maintained by serial passage of fresh infective larvae (L3) through worm-free lambs every 4 months. All lambs used for the production of parasite materials were born and reared indoors in a worm-free environment using elevated wire-bottomed cages. Lambs were infected when 3-6 months old with L3 Ostertagia circumcincta. by oesophageal intubation. For the production of nematode eggs, ram lambs were infected with three doses of approximately 50,000 L3 given on alternate days. Faeces were collected for nematode egg recovery after the pre-patent period. L3 were obtained after hatching the eggs and culturing the larvae in vitro for about 10 days (Denham, 1969). Adult Ostertagia circumcincta were recovered from the mucosal scrapings of these animals necropsied about 10 weeks after infection. Fourth (L4) and fifth (l_5) stage larvae were obtained from abomasal digests of ewe lambs infected with single doses of approximately 500,000 L3 Ostertagia circumcincta and then necropsied between 5-10 days, and 15-20 days respectively, after infection (Herlich, 1956).
b. Extraction of antigens
The extraction buffer was 10mM Tris-HCI, pH 8.0 containing 150mM NaCI, 2mM phenyl- methylsulphanyl fluoride (Sigma, USA), 1mM EDTA (Sigma, USA), 50/ιg/ml L-1-Tosyiamide- 2-phenylethychloro-methyl ketone (Sigma, USA) and 25 μg/ml 2-p-TosyI-L-lysine chloromethyl ketone (Sigma, USA) (Clark, Philip & Parkhouse, 1982; Simpson, James & Sher, 1983). Detergents were added separately at the following concentrations: zwitterionic
- Empigen BB-AU (1% v/v) (Albright & Wilson, Australia) and 3-3-Cholamidopropyl- dimethyiammonio-1-propane-sulfonate (CHAPS) (0.25% w/v) (Sigma, USA); anionic - sodium desoxycholate (1% w/v) (Sigma, USA), N-lauroylsarcosine (1% w/v) (Sigma, USA) and sodium dodecyl sulphate (SDS) (1% v/v) (BDH Chemicals, UK); cationic - cetyitrimethylammonium bromide (CTAB) (0.5 w/v) (Sigma, USA); and nonionic -Triton X-
100 (1 % v/v) (Iso-octylphenolethoxylate [10 units]) [Triton is a Trade Mark of Rohm & Haas Co.] (Boehringer Mannheim, W. Germany) and Nonidet P-40 (0.20% v/v) (Sigma, USA) (Pritchard, Crawford, Duce & Behnke, 1985). Larvae (10,000) or adult worms (100) were washed three times in 10mM phosphate buffered saline (PBS) pH 7.4 and then 0.5 ml of extraction buffer, containing the appropriate detergent, was added. Control sonicates of
Ostertagia circumcincta contained no detergent. Samples were sonicated 10-15 times at
SUBSTITUTE SHEET
4°C for 30 seconds each time at an amplitude of 21 μm when greater than 40% of the worms were broken when an aliquote was examined microscopically. Sonicates were then left overnight at 4°C, vortexed for 30 seconds and centrifuged at 10,000g for 3 minutes. The protein content of each supernatant was then determined by the method of Bradford (1976) using bovine serum albumin (BSA) as the standard.
c. Gel eiectrophoresis and immunoblot procedures
Samples standardised for protein content (25 μg/well) were electrophoresed on 1.5mm, 10% (or 15%) SDS poiyacryiamide gels (SDS - PAGE) using the discontinuous buffer system of Laemmli (1970). Following eiectrophoresis at 60 mA constant current for 3.5 hours, gels were either stained with 0.25% Coomassie Brillant Blue R-250 (BDH Chemicals,
UK) in water: isopropanol: acetic acid at a ratio of 68:25:7 (v/v), or electroblotted onto 0.45 urn nitrocellulose membrance (Schleicher and Schull, West Germany) in a Trans-Blot cell (Bio-Rad Laboratories, USA) at 60 V for 3 hours using the buffer (diluted 1/2) of Towbin, Staehelin & Gordon (1979). The nitrocellulose membrane was then immunostained by first blocking with 5% skim milk containing 0.05% Tween 20 (Sigma, USA) (Batteiger, Newhall
& Jones, 1982) in Tris-buffered saline for 20 minutes. Sheep serum, affinity purified rabbit anti-sheep immunoglobulins (Kirkegaard & Perry Laboratories inc., USA) and peroxidase- conjugated rabbit-antisheep immunoglobulins (Bio-Rad Laboratories, USA) were appropriately diluted in the blocking buffer and consecutively incubated with the blots for 2 hours at 37°C. Blots were washed with four 10 minute changes of blocking buffer after each incubation and developed with 4-chloro-1-napthol (Sigma, USA) (Hawkes, Niday & Gordon, 1982). Where required, blots were treated before the blocking step with either 10 mM periodic acid (BDH Chemicals, UK) (Woodward, Young & Bloodgood), 1985) or Tritirachium album proteinase k (Protease-type XI, Sigma, USA) at a concentration of 100 μg/m in PBS for 24 hours at 37°C.
Two dimensional eiectrophoresis was performed by the method of O'Farrell (1975). For the first dimension, isoelectric focusing was performed in glass tubes using a 1 :1 mixture of pH 5-7 and pH 7-9 ampholytes (Pharmacia, Uppsala, Sweden). SDS-PAGE, using 13% acrylamide slab gels, was used for the second dimension. The gels were stained and fixed in 0.05% w/v Coomassie blue R250 in 50% (v/v) methanol and 10% (v/v) acetic acid for
20 minutes, destained with 5% methanol and 7% acetic acid, then dried under vacuum before autoradiography.
SUBSTITUTE SHEE"
d. Silver staining of gels
On occasion, eiectrophoresis gels were sliver stained by the method of Morrissey (1981). In brief, the gels were rinsed in H20 and soaked in 50% methanol (10% acetic acid fixative for 3 minutes. After a 5 minute immersion in 5% methanol/7% acetic acid solution, the gel was treated with 10% glutaraldehyde for 30 minutes. At this stage the gel was left overnight in a large volume of H20. Following a further wash (30 minutes) in H20, the gel was immersed in a fresh 0.1% AgN03 solution for 30 minutes and then rinsed once in H20 and twice in developer solution (3% Na2C03, 0.05% formalin). The gel was then stained with the developer solution until the desired intensity of staining was achieved. The reaction was arrested by the addition of 2.3 M citric acid (5 ml per 100 ml of developer).
e. Purification of O. circumcincta proteinaceous antigen OC31
The proteinaceous antigen OC31 was purified by preparative eiectrophoresis on a 15% SDS-PAGE gel. Briefly, larval lysates were separated on a 15% SDS-PAGE gel. The gel strip containing the proteinaceous antigen OC31 was excised and the proteins eluted by incubation in PBS at room temperature for 10 hours. The protein content and purity of the 31 kDa extract were assessed by coomassie blue and silver staining after it was re- electrophoresed on another SDS-PAGE gel.
f. Sheep Sera
Sera from sheep carrying monospecific infections with Ostertagia circumcincta were collected from 22 animals bred specifically for their resistance or susceptibility to Ostertagia circumcincta as described previously (Riffkin & Yong, 1984). Briefly, these animals were born and reared indoors under worm-free conditions and at 6 months of age they were assayed for their lymphocyte blastogenic responses to a crude L3 Ostertagia circumcincta antigen preparation in the in vitro micro whole blood lymphocyte culture test (Riffkin & Yong, 1984). They were then infected with a total of 50,000 L3 Ostertagia circumcincta.
Nematode egg outputs were monitored from 3 weeks after infection and total adult worm burdens were recovered at post mortem 10 weeks after infection. Eleven of the 22 sheep were designated as "resistant" because they had high lymphocyte blastogenic indices (S.l.>2.0), low mean egg counts (>200 eggs per gram faeces) and low total adult worm burdens (>30C). The remaining 11 sheep designated as "susceptible" had low lymphocyte blastogenic indices (S.I. >1.2), high mean egg count (> 1,500 e.p.g.) and high total worm burdens (> 1,000) (Yong & Riffkin, 1986). For negative controls, sera were obtained and pooled from 9 uninfected six month old worm-free sheep. AH blood samples were collected
SUBSTITUTE SHEET
in silicone coated vacutainer tubes (Becton Dickinson, USA) and after separation from the clot, the sera were stored at 20°C.
g. FPLC Profiling
Approximately 300 mg of the purified proteinaceous antigen OC31 were reduced in the presence of 1% w/v SDS, 10mM DTT, in 100mM Tris (pH 8.0) for 60 minutes to 58°C. On cooling to ambient temperature, iodoacetamide was added to a final concentration of 22mM and carboxyamidomethylation proceeded for 15 minutes at RT. Protease was added to 1-
2% (w/w), and the mixture precipitated at -20°C (18 hours) in 10 volumes of acetone
(Aristar, BDH). The pelleted material was washed with 2 changes of acid-ethanol and once in ethanol. The pellet was air dried and resolubilized in the buffer of choice. In the case of trypsin digest, the OC31 pellet was taken up in 200μl 1% v/v trimethylamine (pH 8.0), and a further 7μg trypsin (Worthington, Freehold, USA) added. Digestion occurred overnight at 37°C. The chymotrypsin digest was prepared by addition of 200μ 0.1 M
NH4HC03 pH 7.8, (C02) and 10μg chymotrypsin (Worthington) and proteolysis conducted at 37°C for 4 hours. Digestions were arrested by storage at -20°C.
The ensuing peptides were separated by reverse phase chromatography using an organic/aqueous gradient delivered by an FPLC system (Pharmacia). Complete digests were primarily resolved with a 0-92.5% v/v acetonitrile (AcN) gradient in 15-20mM ammonium formate, pH 4.0 (C02) applied over 46 minutes, onto a Pro PRC 5/10 C1/c8 reverse phase column (Pharmacia). The elution was monitored at 214nm.
h. Immunofluoresceπt labelling
Cryostat sections 5-1 Oμm thick of L3 Ostertagia circumcincta were mounted on alcohol- cleaned slides and fixed by immersion in acetone for 5 minutes. After drying at 37°C for 5 minutes, the sections were incubated with 50μl of rabbit anti-OC31 antisera for 1 hour at 37°C in a humidified box. The sections were washed three times in phosphate buffered saline (PBS), incubated with 50μl of a 1/10 dilution of fluorescent anti-rabbit immunoglobulin (Wellcome P/L, Beckenham) for 30 minutes at 37°C,washed again in PBS before mounted with PBS-glyceroI (1 :9) for examination by a lasersharp MRC-500 Scanning Microscope (Bio Rad Laboratories Pty Ltd, Oxfordshire, UK).
SUBSTITUTE SHEET
i. Immunoelectron microscopy
L3 Ostertagia circumcincta were fixed in 2% paraformaldehyde and 0.5% glutaraldehyde, dehydrated (3-5 minutes) in successive concentrations of alcohol (30, 50, 75, 95 and 100%) and infiltrated (2 hour, room temperature) with LR White resin (Timms, 1986). Sections (60 nm) were cut with a diamond knife on a rotary ultramicrotome (Reichert-Jung, Austria) and specimens were picked up onto formvar coated gold (400 mesh) grids (Bio Rad Laboratories Pty Ltd, Oxfordshire). Sections were incubated with rabbit anti-OC31 antiserum (1/5 dilution) for 30 nm at room temperature, washed and then incubated again with a 1/20 dilution of 5 nm gold labelled protein A (Sigma Chemical Company, USA) for 5 minutes, followed by successive treatment with 2.5% glutaraldehyde in PBS for 10 minutes; saturated aqueous uranyl acetate for 5 minutes; and finally lead citrate for 3 minutes. Sections were then washed in 0.2M NaOH and water, dried and examined with an electron microscope (Joel JEM 1005, Japan).
RESULTS
Protein and immunoblot analysis of antigens extracted with different detergents
• The addition of detergents in the extraction buffer generally resulted in a higher yield of protein from L3 and adult Ostertagia circumcincta compared with sonicates extracted without detergents (Table 1). The detergent which yielded the highest protein content under identical extraction conditions from L4 (p<0.01) and adult worm (p<0.025) was Triton X- 100. Similarly, extraction of proteins from sonicates of L3 and audit Ostertagia circumcincta with CHAPS, N-lauroylsarcosine and CTAB was also less efficient than Triton X-100 (data not shown). SDS-PAGE analysis of Triton X-100 sonicates of L3 (lane A, Figure 1) and adult worm (lane C, Figure 1) of Ostertagia circumcincta revealed few differences in protein profiles between these two life cycle stages of the parasite. However, immunoblot analysis using pooled sera from Ostertagia circumcincta infected sheep revealed that there were more antigens recognised in L3 (lane B, Figure 1) than in adult worm (lane D, Figure 1) extracts.
Antigens differentially recognised bv sera from "resistant" sheep
In order to determine whether there were any Ostertagia circumcincta antigens differentially recognised by sera from sheep which had been identified as resistant to this parasite by both immunological and parasitological parameters (Yong & Riffkin, 1986), the antigens in Triton X-100 extracts of L3 Ostertagia circumcincta were probed with sera from 11 resistant and 11 susceptible sheep. A major antigenic band of 31 kilodaiton (kDa) from L3 extract was identified by antibodies in 8 out of eleven sera from resistant sheep (lane b, Figure 2).
SUBSTITUTE SHEET
In experimentally infected resistant animals bled at various times after infection, antibodies to the 31 kDa antigen band appeared in the serum as early as 32 days after infection and persisted until at least 70 days after infection (Figure 3). On the other hand, only 2 out of eleven sera from susceptible sheep reacted with this antigen band, the reaction intensity was much weaker, and detected with sera obtained from animals at post-mortem 70 days after infection compared to those from resistant sheep (lane D, Figure 2). This 31 kDa antigen band did not react with pooled sera from uninfected worm-free sheep (lane F, Figure 2).
TABLE 1
PROTEIN YIELDS FROM Ostertagia circumcincta EXTRACTED USING VARIOUS DETERGENTS
DETERGENT INFECTIVE LARVAE ADULT WORM (ug/ul) (ug/ul)
Triton X-100 0.57 +.0.16* 0.69 ± 0.211
Empigen BB-AU 0.22 ± 0.17 0.49 ± 0.15
Sodium desoxycholate 0.18 ± 0.25 0.16 ± 0.19
Nonidet P-40 0.40 ± 0.12 0.49 ± 0.21
SDS 0.10 ± 0.11 0.60 ± 0.16
No detergent 0.11 + 0.07 0.09 + 0.12
P value + >0.01 > 0.025
mean ± standard deviation of data from 7 experiments, mean ± standard deviation of data from 4 experiments, statistical analysis was carried out using Analysis of Variance.
CHARACTERISATION OF THE 31 kDa ANTIGEN
The 31 kDa antigenic material on a 10% SDS-PAGE is an unusually broad band, and occasionally it has the appearance of a closely associated doublet in certain experiments.
Confirmation of the double banding pattern of this material was obtained by separating the larvae extract on a higher resolution SDS-PAGE gel containing 15% acryiamide and staining the separated proteins with Coomassie blue or probing the proteins with sheep antisera after electroblotting onto a nitrocellulose membrane in the upper and lower bands (Figure 4 ). FPLC profiles of tryptic digests of the reduced and S-carboxymethylated proteins confirm that the two bands are closely related.
SUBSTITUTE SHEET
The protein doublet 0C31 can readily be stained with carbohydrate silver stain which suggested that it is a glycoprotein. However, the sugar content of 0C31 is only 5-15% of the total molecular complex as indicated by phenol/sulphuric acid assay for hexose sugars. GC mass spectrometric analysis identified the presence of inositol, mannose, galactose and hexosamine residues in the carbohydrate moiety. In addition Boehringer gylcan detection kit (Boehringer Mannheim, W. Germany) revealed the presence of giycan when the glycan detection kit was used in immunoblot. Neither proteinase K nor periodate oxidation treatments abolished the immunological activity of 0C31 suggesting the presence of epitopic structures other than those normally conferred by peptides (Figure 5).
Apart from its detection in L3 preparations, the protein doublet 0C31 antigen is not found in Triton X-100 sonicates of L4, L5 and adult Ostertagia circumcincta (lane A, Figure 2).
Extracts of L3 Ostertagia circumcincta" probed with sera from Ostertagia circumcincta infected sheep were more immunoreactive than those of adult Ostertagia circumcincta (Figure 1). In contrast to these findings Maizels, Meghji & Ogilvie, (1983) reported that Nippostronoylus braslliensis adults had the greatest number of antigens recognised by immune sera compared to larval stages. Parkhouse & Clark (1983) also found few major antigens in L3 and many antigens in immunoprecipitates of adult Trichinella spiralis. It would appear therefore, that the predominant antibody response elicited by a nematode is stage specific and that the most immunogenic stage differs between nematodes.
LOCALISATION OF OC31
The internal distribution of the proteinaceous antigen OC31 was observed in cryostat sections of L3 Ostertagia circumcincta immunostained with rabbit anti-OC31 antibodies and fluorescent anti-rabbit immunoglobulin. Both the cuticular and hypodermal layers were non- fluorescent areas and were readily seen (Figure 6). To further define the structures responsible for fluorescence, serial sections of L3 Ostertagia circumcincta were examined under an electron microscope after immuno-staining. Specific deposition of electron-dense gold particles was seen in "secretory organelles" of transverse sections taken from the anterior pharyngeal region of the larvae (Figure 7). No gold particles were detected in similar sections of L3 Ostertagia circumcincta which had been exposed to normal rabbit sera.
SUBSTITUTE SHEET
The internal location of the immunogold label to the secretory organelles was highly specific and reproductible. The biological function of OC31 is not known but the secretory organelles in the oesophageal glands are thought to discharge via the lumen of the oesophagus (Lee, 1968, 1970). The localisation of OC31 in the secretory organelles had further suggested that these molecules could be excreted/secreted by the larvae.
Metabolic labelling of L3 Ostertagia circumcincta and immunoprecipitation analysis of the excreted/secreted material provided evidence that OC31 is probably an excretory/secretory product. Other low molecular weight antigens secreted by living worms have been described (Lightowlers & Rickard, 1988).
SPECIES DISTRIBUTION OF OC31
In order to determine whether the proteinaceous antigen OC31 was unique to L3 Ostertagia circumcincta. Triton X-100 extracts of infective larval stages of other nematode species were probed with serum from Ostertagia circumcincta infected resistant sheep. Figure 8 is an autoradiograph of an immunoblot, probed with resistant sheep serum and developed using protein G 125l (Amersham), showing the predominant 31 kDa band is a group of molecules
(arrow) of third stage Ostertagia circumcincta (lane A) present in Triton X-100 extracts of third stage larvae of Trichostrongylus colubriformis (lane B) and Haemonchus contortus (lane C), but not well represented in second stage larvae of Toxocara canis (lane D).
The OC31 antigen (Figure 8 lane A) was found to be present in extracts of infective larvae of Trichostrongylus colubriformis (Figure 8 lane B) and Haemonchus contortus (Figure 8 lane C), but not in Toxocara canis (Figure 8, lane D). Similar results were obtained with monospecific rabbit anti-OC3l serum. It is well established that the stimulation of specific immune responses, by a given species of nematode parasite, may protect the host against infection by other nematode species. For example, Blanchard & Wescott (1985) have recently shown that previous infection with Ostertagia circumcincta enhances the resistance of lambs to Haemonchus contortus infection. While it is possible that these observations are accounted for by the stimulation of non-specific mechanisms, OC31 could well be an important cross-reactive or common antigen involved in the protective immune response of sheep to other gastrointestinal nematode species. Milner, Beall & Orwat (1987) have indicated that there may be considerable homology between antigens of Trichostrongylus colubriformis and Ostertagia circumcincta. they stated that the majority of proteins detected were shared by each species, but failed to specifically identify any particular antigens for meaningful comparisons.
SUBSTITUTE SHEET
VACCINATION TRIAL WITH THE NATIVE PROTEINACEOUS ANTIGEN OC31
a. Experimental Design
Eleven 6 month old lambs, reared indoors in a worm free environment from birth, were randomised on the basis of pre-immunisation ELISA titres to the proteinaceous antigen OC31 into treatment (N=6) and control (N=5) groups respectively.
The treatment group were given an initial intradermal injection of 100 μg of the purified proteinaceous antigen OC31 in Quil A adjuvant (Harcros International Chemicals, Australia). Identical booster injections were given 3 weeks later and thereafter at weekly intervals for two weeks. Each immunisation and booster injection consisted of 100 μg of the OC31 containing 250 μg/ml of Quil A in 10 mM phosphate buffered saline, pH 7.4 in a final volume of 2 ml. Control animals received the same regimen of immunisation and booster injections excluding only the purified proteinaceous antigen OC31.
Both control and treated groups were infected with three doses of 14,000 L3 Ostertagia circumcincta given on alternate days (total /animal 42,000 larvae) commencing 6 weeks after the initial immunisation injection (one week after the third and final booster immunisation).
b. Faecal egg counts
Faecal egg counts (F.E.C.) were carried out using the quantitative floatation method described by Gibson (1965). Briefly, faecal samples were collected daily, in the morning, from each animal. 2.0g samples were thoroughly mixed with 10 ml of water and allowed to stand for 5 minutes. Saturated salt (NaC1, S.G. 1.20) was then added to 60 ml. The suspension was stirred thoroughly and aliquots were then transferred to McMaster egg counting slides.
c. Collection of blood samples
Blood samples from sheep were collected prior to commencement of immunisation and thereafter prior to each immunisation injection at the day of challenge and at weekly intervals thereafter until necropsy at 10 weeks post immunisation.
d. Immunblots and enzyme linked immunosorbent assay (ELISA)
immunoblot procedures have been previously described. Briefly, L3 Ostertagia circumcincta Triton X-100 sonicate was resolved by sodium dodecyi sulfate-polyacryiamide gel eiectrophoresis (Laemmli, 1970) and electrophoretically transferred to nitrocellulose paper (Schleucher Schull, West Germany) as described by Towbin et al (1979). Blocking
SUBSTITUTE SHEET
and wash buffer consisted of 5% non-fat milk powder containing 0.05% Tween 20 (Sigma Chemical Company, Missouri) in Tris-buffered saline, and colour development was carried out using 4-chIorc-1-naptho! (Sigma Chemical Company, Missouri) (Hawkes §!§! 1982).
5 EUSAs were carried out using flat bottomed microtitre trays (Immunlon, Dynatech
Laboratories) coated with 10 μg/ml (0.5 μg/well) of purified OC31 antigen in carbonate- bicarbonate buffer, pH 9.6, by incubation at room temperature for 1 hour. Sheep antiserum diluted 1:500 in PBS, pH 7.4 containing 1% bovine serum albumin (Sigma Chemical Company, Missouri) was added. After incubation at room temperature for 2 hours, the trays
10. were washed three times with PBS containing 0.05% Tween 20. Bound sheep OC31 antibody was then reacted with HPRO conjugated rabbit antisheep immunoglobulins (Kirekgaard & Perry Laboratories Inc., USA) and incubated at room temperature for 2 hours. After 3 washes in PBS followed by 3 washes in distilled water, ABTS colour development substrate was added (100 ul/well) and the colour reaction developed for 1 hour at room
15 temperature. The absorbance (OD) of the enzyme substrate reaction product was measured at 450 nm in an automatic micro ELISA reader (Model MR580; Dynatech Laboratories). Uninfected sheep serum was used as a negative control in each test tray.
e. Lymphocyte blastogenic indices
Lymphocyte blastogenic responses of control and vaccinated sheep to the purified OC31 20 antigen were assayed in an in vitro micro whole blood lymphocyte culture test described by Riffkin & Yong (1984). Briefly, 0.2 mi blood samples were collected from each sheep and immediately added to 2.4 ml of sterile HEPES (25 mM) buffered RPMI 1640 culture medium supplemented with 4% heat inactivated foetal calf serum, 100 units/ml sodium penicillin and 100 μg/ml streptomycin sulphate.
25 0.1 ml aliquots of diluted whole blood were dispensed into round bottomed microtest plates (Nunclon, A/S Nunc Denmark). 25 μl of mitogens, antigens and plain medium (control) were then added to triplicate wells. The plates were sealed with polypropylene tape (Dynatech), mixed for 15 seconds on a microplate shaker and incubated at 37°C until the cells were harvested 4 days later. Sixteen hours before harvesting each culture received
30 3.7 kBq tritiated thymidine (specific activity 185 G Bq dispensed in 25 μl RPM1 1640). The cultures were then mixed and harvested onto glass fibre filter paper discs using a multiple cell harvester (Flow Lab). Erythrocyte lysis (15 seconds distilled water), bleaching (10 seconds H202), dehydration (10 seconds methanol) and drying (20 seconds in air) were carried out before drying filter paper discs in a 60°C oven for 10-15 minutes. Finally each
35 disc was placed into 2m! of toluene based scintillation fluid and then counted in a liquid scintillation spectrophotometer.
SUBSTITUTE SHEET
f. Total worm counts
For total worm counts, the abomasum was dissected out at post mortem after clamping the duodenum just below the pyloric sphincter. The greater curvature of the abomasum was slit and opened flat. The contents were washed with PBS pH 7.2, and collected together with the mucosal scrapings. The combined washes and scrapings were then concentrated and cleaned by repeated refilling and shaking in a 600 ml screw top jar (with a 317 μm sieve inserted in the lid) until the discharged water was clear. Adult worms were individually picked and counted with the aid of a dissecting microscope. Pepsin digestion of the abomasa after scraping was carried out to determine the number of immature worms. Pepsin digestion was carried out in PBS containing 2% HCI and 1.6% pepsin (Sigma
Chemical Company, Missouri, USA), at 42°C for 3 hours, with frequent shaking. Immature worms were collected from the abomasal digest by washing through a 38 μ m sieve.
g. Histopathology
Formalin fixed, paraffin embedded tissues from the abomasa of control and vaccinated sheep were obtained at necropsy, stained by Haematoxyiin and Eosin (H & E) and examined by light microscopy.
RESULTS
Evaluation of mmunisation
Humoral OC31 antibody levels in vaccinated and control sheep were monitored by EUSA and immunoblot analyses throughout the course of the experiment. Cell mediated immune responses were assayed using peripheral lymphocyte stimulation indices. Evaluation of the course of parasite infection was determined by monitoring faecal egg counts on a daily basis from day 28 after challenge until the day before necropsy. After necropsy the total worm counts were carried out.
The ELISA antibody responses of sheep immunised with OC31 are shown in Figure 9.
Elevated levels of OC31 antibodies were detected as early as two weeks after the first immunisation dose in vaccinated sheep. Compared with the control animals OC31 antibody titres rose steadily in the vaccinated group and remained at a high level throughout the duration of the experiment. Immunoblots probed with serum taken from vaccinated sheep during the course of the experiment demonstrated and confirmed the appearance of OC31 antibodies four days after the first booster immunisation. In control animals no OC31 antibodies were detected in immunoblots throughout the course of the experiment.
| SUBSTITUTE SHEET
immunisation with the OC31 antigen resulted in a marked and specific cell mediated response of peripheral lymphocytes (Table 2) as detected by the in-yrtro whole blood lymphocyte culture assay. A heightened response during the preinfection immunisation program was still significant at post-infection but tailed off by the end of the experiment. Examination of the H & E sections indicated that in vaccinated animals there were more larvae present in the dilated crypts compared to control animals and these larvae were surrounded with eosinophils. in H & E sections from vaccinated animals, a massive infiltration of lymphocytes in the lamina propria and oedema in the sub-mucosa and muscle layers were observed. TABLE 2
CELL-MEDIATED RESPONSE OF VACCINATED AND CONTROL SHEEP
IMMUNISED WITH THE PROTEINACEOUS ANTIGEN OC31 OF
L3 OSTERTAGIA CIRCUMCINCTA
Positive stimulation index is defined as 2 or above.
Statistical analysis was carried out using a split plot (animals split for time) analysis of variance. Treatment was allocated to six animals at random, the remaining animals were controls.
# C = control; V= vaccinated
Nematode Burden
The faecal egg outputs of immunised sheep were significantly lower (P<0.05) than those of the control sheep (Figure 10). Similarly the total worm counts were significantly lower
SUBSTITUTE SHEET
(P< 0.005) from immunised animals than from control animals as shown in TABLE 3.
TABLE 3
Ostertagia circumcincta ADULT WORM BURDENS IN THE
ABOMASA OF VACCINATED AND CONTROL SHEEP AT POST MORTEM
Group df# mean range P value*
control + 4 6047 3860-9900 vaccinated 5 2555 1175-3647 P< 0.005
+ adult worm count for one of the control sheep was unable to be calculated.
* statistical analysis was carried out using the Pitman randomisation test rather than analysis of variance because the necessary assumptions of normality and homogeneity of variance were not satisfied, even under log transformation.
# degree of freedom
These experiments indicate an immune response after administering unusually low levels of the vaccine according to the invention. It is not known why the present vaccine is so efficacious, but it may be as a result of using a relatively pure fraction of the active material, thereby avoiding blocking effects.
Since modifications within the spirit and scope of the invention may be readily effected by persons skilled in the art, it is to be understood that the invention is not limited to the particular embodiments described, by way of example, hereinabove.
SUBSTITUTE SHEET
REFERENCES
ANDERS, R.F, HOWARD, R.J and MITCHELL, G.F 1982. In: Immunology of Parasitic Infections. S Cohen & K S Warren, Editors, Blackwell Scientific Publications, Oxford, p.28.
BATTEIGER, B., NEWHALL, W.J. and W.J. and JONES, R.B. 1982. J Immunol. Methods 55: 297
BLANCHARD, J.L and WESCOTT, R.B. 1985. Am J. Vet. Res. 46:2136
BRADFORD, M.M. 1976. Anal Biochem 72:248
CLARK, N.W.T., PHILIPP, M. and PARKHOUSE, R.M.E. 1982. Biochem. J 206:27
DENHAM, D.A. 1969. J. Helminth 43:299
GIBSON, T.E. 1965. Manual of Parasitological Techniques. Ministry of Agriculture, Fisheries and Food Central Veterinary Laboratory, Weybridge, England
HAWKES, R.E., NIDAY, E. and GORDON J. 1982. Anal. Biochem. 119:142
HERLICH, H. 1956. Proc. Helminth. Soc. Wash. 23:102
LAEMNLI, N.K. 1970. Nature 227:680
LEE. D.L 1968. J. Zool 154(b) :9
LEE, D.L. 1970. Tissue and Cell 2:225
LIGHTOWLERS, M.W. and RICKARD, M.D. 1988. Parasitoloov 96:123
MAIZELS, R.M., MEGHJI, M. and OGILVIE, B.M. 1983. Immunology 48:107
MILNER, A.R., BEALL, J.A. and ORWAT, A. 1987. Parasit. Immunol. 9:615
MORRISSEY. J.H. 1981. Anal Biochem 117:307
SUBSTITUTE SHEET
O'DONNELL, I.J., DINEEN, J.K., WAGLAND, B.M., LETHO, S., WERKMEISTER, J and WARD, C.W. 1989. Int. J. Parasitol. 12:327
O'DONNELL, I.J., DINEEN, J.K., WAGLAND, B.M., LETHO, S. DOPHEIDE, T.A.A., GRANT, W.M. and WARD, C.W. 1989. Int. J. Parasitol. 19:793
O'FARRELL. P.H.. 1975. J.Biol. Chem. 250:4007
PARKHOUSE, R.M.E. and CLARK, N.W.T. 1983. Mol. Biochem. Parasitol. g:319
PRITCHARD, D.I., CRAWFORD, C.R., DUCE, I.R. and BEHNKE, J.M. 1985. Parasit. Immunol 7:575
RIFFKIN, G.G. and YONG, W.K. 1984. In: Immunogenic Approaches to the Control of Endoparasites. with Particular Reference to Parasites of Sheep. J.K. DINEEN & P.M.
OUTTERIDGE, P.M., EDITORS, Australian Wool Corporation and CSIRO Division of Animal Health, Australia, p.30.
SIMPSON, A.J.G., JAMES, S.L and SHER, A. 1983. Inf. Imm. 41:591
TIMMS, B.G. 1986. Am. J. Anat. 175 2:267
TOWBIN, H.T., STAEHELIN, T. and GORDON, J. 1979. Proc. Natl. Acad. Sci. U.S.A.
76:4350
WOODWARD, M.P., YOUNG, W.W., Jrand BLOODGOOD, R.A. 1985. J. Immunol. Methods 78:143
YONG, W.K. and RIFFKIN, G.G. 1986. In: Proceedings of the sixth International Congress of Parasitoloαv. M.J. Howell, Editor, Australian Academy of Science, Canberra, p.262.
DARATECH PTY LTD by its Patent Attorney David V Gibson, 17 July, 1990.
SUBSTITUTE SHEET i
Claims (12)
1. A non-living veterinary vaccine comprising a proteinaceous antigen OC31 of molecular weight about 31 kilodaiton as determined by SDS-PAGE extracted from species of gastrointestinal nematode parasites belonging to the phylum Nemathelminthes, class Nematoda, order Strongloidea.
2. A vaccine as defined in claim 1 wherein the antigen is an excretory/secretory and metabolic product of Ostertagia circumcincta.
3. A vaccine as defined in claim 1 wherein the antigen is an intracellular, somatic and membraneous extract of Ostertagia circumcincta.
4. A vaccine as defined in either claim 2 or 3 wherein the antigen is produced by Triton X-100 extraction with or without any other detergents from infective third stage larvae or Ostertagia circumcincta.
5. A vaccine as defined in claim 1 wherein the antigen is an excretory/secretory and metabolic product of Haemonchus contortus.
6. A vaccine as defined in claim 1 wherein the antigen is an intracellular, somatic and membranous extract of Haemonchus contortus.
7. A vaccine as defined in claim 1 wherein the antigen is produced by Triton X-100 extraction or by extraction with or without any other detergents from infective third stage larvae of Haemonchus contortus.
8. A vaccine as defined in Claim 1 wherein the antigen is an excretory/secretory and metabolic product of Trichostrongylus colubriformis
9. A vaccine as defined in Claim 1 wherein the antigen is an intracellular, somatic and membranous extract of Trichostrongylus colubriformis.
10. A vaccine as defined in Claim 1 wherein the antigen is produced by Triton X-100 extraction or by extraction with or without any other detergents from infective third stage larvae of Trichostrongylus colubriformis.
11. A vaccine as defined in any one of Claim 1-10 further comprising an adjuvant.
12. A method of treating animals by administering an effective dose of a vaccine as defined in any one of Claims 1-11.
SUBSTITUTE SHEET
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19900910537 EP0486507A4 (en) | 1989-07-21 | 1990-07-17 | Anthelmintic non-living vaccine |
PCT/AU1990/000306 WO1991001150A1 (en) | 1989-07-21 | 1990-07-17 | Anthelmintic non-living vaccine |
AU59614/90A AU638728B2 (en) | 1989-07-21 | 1990-07-17 | Anthelmintic non-living vaccine |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPJ538589 | 1989-07-21 | ||
AUPJ5385 | 1989-07-21 | ||
AU59614/90A AU638728B2 (en) | 1989-07-21 | 1990-07-17 | Anthelmintic non-living vaccine |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5961490A AU5961490A (en) | 1991-02-22 |
AU638728B2 true AU638728B2 (en) | 1993-07-08 |
Family
ID=25632496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU59614/90A Ceased AU638728B2 (en) | 1989-07-21 | 1990-07-17 | Anthelmintic non-living vaccine |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0486507A4 (en) |
AU (1) | AU638728B2 (en) |
WO (1) | WO1991001150A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9322702D0 (en) * | 1993-11-03 | 1993-12-22 | Agricultural & Food Res | Vaccines |
GB0913511D0 (en) * | 2009-08-03 | 2009-09-16 | Moredun Res Inst | Parasite harvesting |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4336089A (en) * | 1988-09-26 | 1990-04-18 | Biotechnology Australia Proprietary Limited | Vaccine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2355507A1 (en) * | 1976-06-25 | 1978-01-20 | Inst Nat Sante Rech Med | ORAL ANTIPARASITIC VACCINE, ITS PREPARATION PROCEDURE AND ITS APPLICATION METHOD IN MAMMALS |
-
1990
- 1990-07-17 WO PCT/AU1990/000306 patent/WO1991001150A1/en not_active Application Discontinuation
- 1990-07-17 EP EP19900910537 patent/EP0486507A4/en not_active Withdrawn
- 1990-07-17 AU AU59614/90A patent/AU638728B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4336089A (en) * | 1988-09-26 | 1990-04-18 | Biotechnology Australia Proprietary Limited | Vaccine |
Also Published As
Publication number | Publication date |
---|---|
WO1991001150A1 (en) | 1991-02-07 |
AU5961490A (en) | 1991-02-22 |
EP0486507A1 (en) | 1992-05-27 |
EP0486507A4 (en) | 1993-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smith | Protection in lambs immunised with Haemonchus contortus gut membrane proteins | |
Smith et al. | Maternal transfer of antibodies induced by infection with Eimeria maxima partially protects chickens against challenge with Eimeria tenella | |
Rodríguez-Mallon | Developing anti-tick vaccines | |
Tarigan et al. | Failure to protect goats following vaccination with soluble proteins of Sarcoptes scabiei: evidence for a role for IgE antibody in protection | |
Grayson et al. | Immunization of Atlantic salmon against the salmon louse: identification of antigens and effects on louse fecundity | |
JP2759652B2 (en) | Proteins, methods for extracting proteins, vaccines and methods for immunizing ruminants | |
Innocenti et al. | Larval salivary gland proteins of the sheep nasal bot fly,(Oestrus ovis L.), are major immunogens in infested sheep | |
Tellam et al. | Inhibition of growth of Lucilia cuprina larvae using serum from sheep vaccinated with first-instar larval antigens | |
O'Donnell et al. | Characterization of the major immunogen in the excretory-secretory products of exsheathed third-stage larvae of Trichostrongylus colubriformis | |
Skelly et al. | The humoral immune response of sheep to antigens from larvae of the sheep blowfly (Lucilia cuprina) | |
AU638728B2 (en) | Anthelmintic non-living vaccine | |
EP1363937B1 (en) | Immunomodulating agents from parasitic worms and method for isolation thereof | |
McGillivery et al. | A purified stage-specific 31 kDa antigen as a potential protective antigen against Ostertagia circumcincta infection in lambs | |
CA2103788A1 (en) | Reagents and methods for identification of vaccines | |
Kimaro et al. | Tick infestations on cattle vaccinated with extracts from the eggs and the gut of Boophilus microplus | |
Toaleb et al. | Evaluation of vaccine candidates purified from the adult ticks of Ornithodoros savignyi (Acari: Argasidae) and Hyalomma dromedarii (Acari: Ixodidae) against tick infestations | |
EP0381427B1 (en) | Vaccine Composition | |
NZ234612A (en) | Non-living veterinary vaccine against nematode parasites comprising an oc31 antigen | |
Lello et al. | Cell-mediated and humoral immune responses in immunized and/or Dermatobia hominis infested rabbits | |
Takahashi et al. | Ultrastructural localization of antigenic substances in Trichinella spiralis | |
McGillivery et al. | Extraction and identification of a 31,000 mol. wt glycoprotein antigen of Ostertagia circumcincta by sera from resistant sheep | |
McGillivery et al. | The distribution and localization of the stage-specific GP31 antigen from infective Ostertagia circumcincta larvae | |
Anjili et al. | Effects of anti-Leishmania monoclonal antibodies on the development of Leishmania major in Phlebotomus duboscqi (Diptera: Psychodidae) | |
EP0505034A2 (en) | Immunogens derived from pathogen-free tick species or cell lines, and tick vaccines derived therefrom | |
Kandil et al. | Fractionation and Characterization of Different Protein Extracts from Hyalomma dromedarii(Acaris: Ixodidae) |